This tutorial will provide an overview of the emerging field of Cardio-Oncology and associated cardiotoxicity. The AHA/ACC Heart Failure Guidelines define individuals with exposure to cardiotoxic medications, as ‘at risk’ for heart failure, or Stage A. An understanding of the types of oncologic treatments and the pathophysiological mechanisms that are associated with cardiotoxicity provides the foundation for optimal cardiovascular care and surveillance of patients receiving cardiotoxic agents.
- Review the current and future burden of cardiotoxicity related cancer therapies
- Recognize the cardiotoxic effects of chemotherapeutics and radiation therapies
- Define the pathophysiological mechanisms underlying the cardiotoxic effects of cancer therapies
Joerg Herrmann, M.D.
Associate Professor of Medicine
Division of Cardiovascular Diseases
Mayo Clinic, Rochester, MN
$40 - Streaming Video
$50 - Streaming Video and DVD